Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Value
New
Ideas
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Portfolio
News
Enterprise Solutions
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Arrived
EquityMultiple
Follow Us
More
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Premium Newsletters
Smart Value
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Calculators
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Ratings
Alnylam Pharmaceuticals: Balancing Promising Pipeline with Competitive Challenges and Strategic Uncertainties
13d ago
ALNY
Premium
Ratings
Alnylam Pharma’s Strategic Advancements and Promising Pipeline Drive Buy Rating
14d ago
ALNY
Premium
Ratings
Cautious Hold on Alnylam Pharmaceuticals Amid Promising Pipeline and Pending Approvals
14d ago
ALNY
Premium
Ratings
Alnylam Pharma’s Promising Pipeline and Strategic Advancements Justify Buy Rating
14d ago
ALNY
Premium
Ratings
Alnylam Pharma’s Promising Growth Prospects: Buy Rating Backed by Strong Pipeline and Strategic Focus
14d ago
ALNY
Premium
Ratings
Strategic Growth Potential and Robust Pipeline Reinforce Buy Rating for Alnylam Pharma
14d ago
ALNY
Premium
Ratings
Alnylam Pharma’s TTR Franchise Growth and Transition to Nucresiran Drives Buy Rating
16d ago
ALNY
Premium
The Fly
Alnylam to host research and development day
17d ago
ALNY
Premium
The Fly
Alnylam price target raised to $385 from $384 at Canaccord
22d ago
ALNY
Premium
Ratings
Alnylam Pharma: Hold Rating Due to Stable Financials and Uncertain Pipeline Prospects
23d ago
ALNY
Premium
Company Announcements
Alnylam Pharmaceuticals’ Earnings Call Highlights Strong Growth
24d ago
ALNY
Premium
The Fly
Alnylam price target lowered to $300 from $310 at Scotiabank
26d ago
ALNY
Premium
Ratings
Strong Buy Recommendation for Alnylam Pharma Amid Upcoming PDUFA Date and Promising Growth Prospects
26d ago
ALNY
Premium
Company Announcements
Alnylam Pharmaceuticals Reports Strong 2024 Growth
27d ago
ALNY
Premium
Ratings
Alnylam Pharma Receives Buy Rating: Strong Revenue Growth, Regulatory Approvals, and International Expansion Fuel Positive Outlook
27d ago
ALNY
Premium
Ratings
Alnylam Pharma’s Promising Outlook: Buy Rating Backed by Strong Sales, Strategic Developments, and Profitability Potential
27d ago
ALNY
Premium
The Fly
Alnylam sees FY25 revenue $2.05B-$2.25B, consensus $2.68B
27d ago
ALNY
Premium
The Fly
Alnylam reports Q4 EPS (6c), consensus (14c)
27d ago
ALNY
Premium
Pre-Earnings
Alnylam Pharmaceuticals (ALNY) Q4 Earnings Cheat Sheet
29d ago
ALNY
Premium
The Fly
Alnylam treatment of ATTR amyloidosis granted orphan designation
1M ago
ALNY
Premium
The Fly
Alnylam added to US Conviction List at Goldman Sachs
1M ago
ALNY
Premium
The Fly
Alnylam positive reaction to guidance ‘makes sense,’ says JPMorgan
2M ago
ALNY
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
